Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of KU-0059436 with carboplatin and/or paclitaxel in advanced solid tumors
NL-OMON46952Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olaparib in Nonhematologic neoplasms, ovarian cancer and triple-negative breast cancer (TNBC) (6 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability and PARP-inhibitory dose / maximum tolerated dose. Started Jul 2007; status: recruiting.
02
Drugs
olaparib
03
Conditions
Nonhematologic neoplasmsovarian cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON46952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46952.